Bimatoprost analogue - SpyGlass Pharma
Alternative Names: Second generation bimatoprostLatest Information Update: 21 Oct 2022
At a glance
- Originator SpyGlass Pharma
- Class Amides; Antiglaucomas; Eye disorder therapies; Lipids; Prostaglandins; Small molecules
- Mechanism of Action Prostaglandin F2alpha receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Glaucoma
Most Recent Events
- 21 Oct 2022 Early research in Glaucoma in USA (Intraocular) prior to October 2022 (SpyGlass Pharma website, October 2022)